

# Luca Baldini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8600733/publications.pdf>

Version: 2024-02-01

148  
papers

6,174  
citations

87401

40  
h-index

81351

76  
g-index

149  
all docs

149  
docs citations

149  
times ranked

7063  
citing authors

#	ARTICLE	IF	CITATIONS
1	Demystifying the diagnostic criteria of indolent systemic mastocytosis. <i>Hematological Oncology</i> , 2022, 40, 123-125.	0.8	0
2	Impact on thrombotic risk of canonical and atypical CALR mutations in essential thrombocythemia. A single-center cohort study. <i>Thrombosis Research</i> , 2022, 210, 67-69.	0.8	3
3	Clinical, Morphological and Clonal Progression of VEXAS Syndrome in the Context of Myelodysplasia Treated with Azacytidine. <i>Clinical Hematology International</i> , 2022, 4, 52-55.	0.7	7
4	Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse. <i>Leukemia and Lymphoma</i> , 2022, 63, 2743-2746.	0.6	2
5	Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series. <i>Hematological Oncology</i> , 2021, 39, 123-128.	0.8	1
6	Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , 2021, 39, 141-144.	0.8	3
7	What Is New in the Treatment of Smoldering Multiple Myeloma?. <i>Journal of Clinical Medicine</i> , 2021, 10, 421.	1.0	7
8	A brief rituximab, bendamustine, mitoxantrone (R <sup>2</sup> BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2021, 193, 280-289.	1.2	4
9	Imaging a unicuspid aortic valve with transillumination. <i>Echocardiography</i> , 2021, 38, 504-505.	0.3	0
10	Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 637116.	1.3	15
11	Chromosomally integrated human herpesvirus 6 (ci-HHV-6) in autologous bone marrow transplant recipients: are we missing a reactivation or is it just mimicking?. <i>Journal of Clinical Virology</i> , 2021, 139, 104823.	1.6	0
12	Safety of outpatient stem cell mobilization with low or intermediate dose cyclophosphamide in newly diagnosed multiple myeloma patients. <i>European Journal of Haematology</i> , 2021, 107, 566-572.	1.1	1
13	Distinct Metabolic Profile Associated with a Fatal Outcome in COVID-19 Patients during the Early Epidemic in Italy. <i>Microbiology Spectrum</i> , 2021, 9, e0054921.	1.2	6
14	Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 6479-6490.	3.2	9
15	Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity. <i>Cancers</i> , 2021, 13, 4898.	1.7	8
16	Co-Occurrence of Myeloid and Lymphoid Neoplasms: Clinical Characterization and Impact on Outcome. A Single-Center Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 701604.	1.3	3
17	Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib. <i>Frontiers in Oncology</i> , 2021, 11, 734025.	1.3	0
18	Dissection of Bone Marrow Microenvironment By Single Cell RNA Sequencing in Warm AIHA Patients: A Proof-of-Concept Analysis. <i>Blood</i> , 2021, 138, 931-931.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse. <i>British Journal of Haematology</i> , 2020, 188, 907-917.	1.2	8
20	New Perspectives on Polycythemia Vera: From Diagnosis to Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5805.	1.8	27
21	Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma. <i>HemaSphere</i> , 2020, 4, e402.	1.2	15
22	Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 5616-5630.	2.5	10
23	Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact. <i>Frontiers in Oncology</i> , 2020, 10, 506.	1.3	21
24	Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma. <i>Cancers</i> , 2020, 12, 1332.	1.7	7
25	Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma. <i>Hematological Oncology</i> , 2020, 38, 439-445.	0.8	4
26	NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome. <i>Non-coding RNA</i> , 2020, 6, 11.	1.3	11
27	Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy). <i>Blood Advances</i> , 2020, 4, 2996-2999.	2.5	7
28	Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , 2020, 38, 406-408.	0.8	5
29	Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications. <i>Frontiers in Immunology</i> , 2020, 11, 569381.	2.2	26
30	Simultaneous Home Palliative Care in Onco-Hematological Patients: An Italian Single Institution Experience. <i>Blood</i> , 2020, 136, 2-3.	0.6	0
31	Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma. <i>Blood</i> , 2020, 136, 3-4.	0.6	0
32	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network. <i>American Journal of Hematology</i> , 2019, 94, 1193-1199.	2.0	18
33	UGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E283-E285.	2.0	4
34	Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach. <i>Hematological Oncology</i> , 2019, 37, 424-433.	0.8	3
35	Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. <i>Journal of Hematology and Oncology</i> , 2019, 12, 4.	6.9	27
36	A case report of systemic mastocytosis associated with multiple hematologic non-mast cell lineage diseases. <i>Hematological Oncology</i> , 2019, 37, 205-211.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. <i>Hematological Oncology</i> , 2019, 37, 160-167.	0.8	15
38	Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability. <i>Blood</i> , 2019, 134, 5555-5555.	0.6	0
39	Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. <i>Haematologica</i> , 2018, 103, e245-e248.	1.7	29
40	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study). <i>Oncologist</i> , 2018, 23, 1033-1038.	1.9	3
41	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1357-1366.	1.2	8
42	Absolute monocyte count at diagnosis could improve the prognostic role of early <sup>18</sup> F-FDG-PET in classical Hodgkin lymphoma patients. <i>British Journal of Haematology</i> , 2018, 180, 600-602.	1.2	2
43	Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 9-16.	2.0	13
44	Global methylation patterns in primary plasma cell leukemia. <i>Leukemia Research</i> , 2018, 73, 95-102.	0.4	13
45	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. <i>Oncotarget</i> , 2018, 9, 23443-23450.	0.8	12
46	A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up. <i>Acta Haematologica</i> , 2017, 137, 7-14.	0.7	4
47	Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosing Hodgkin lymphoma: results of a large multicenter study involving 990 patients. <i>Hematological Oncology</i> , 2017, 35, 561-566.	0.8	36
48	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016, 101, e196-e199.	1.7	15
49	Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2016, 34, 1175-1181.	0.8	94
50	Compendium of <i>FAM46C</i> gene mutations in plasma cell dyscrasias. <i>British Journal of Haematology</i> , 2016, 174, 642-645.	1.2	34
51	Primary plasma cell leukemia 2.0: advances in biology and clinical management. <i>Expert Review of Hematology</i> , 2016, 9, 1063-1073.	1.0	15
52	A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 880-887.	0.6	9
53	Molecular spectrum of <i>TP53</i> mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature. <i>Oncotarget</i> , 2016, 7, 21353-21361.	0.8	40
54	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , 2015, 125, 1922-1931.	0.6	53

#	ARTICLE	IF	CITATIONS
55	Polarimetric radar for civil aircrafts to support pilots' decision in bad weather conditions. , 2015, , .		5
56	Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients. Mayo Clinic Proceedings, 2015, 90, 756-764.	1.4	39
57	Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). Clinical Lymphoma, Myeloma and Leukemia. 2015, 15, 75-85.	0.2	32
58	Molecular spectrum of <i>BRAF</i> , <i>NRAS</i> and <i>KRAS</i> gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Oncotarget, 2015, 6, 24205-24217.	0.8	65
59	A compendium of <i>DIS3</i> mutations and associated transcriptional signatures in plasma cell dyscrasias. Oncotarget, 2015, 6, 26129-26141.	0.8	40
60	Neutrophil - Lymphocyte Ratio (NLR) at Diagnosis Is an Independent Prognostic Factor in Patients with Nodular Sclerosis Hodgkin Lymphoma: Results of a Large Multicenter Study Involving 990 Patients. Blood, 2015, 126, 3862-3862.	0.6	0
61	Molecular events underlying interleukin-6 independence in a subclone of the CMA3 multiple myeloma cell line. Genes Chromosomes and Cancer, 2014, 53, 154-167.	1.5	6
62	Defining the best cutoff value for lymphopenia in diffuse large B cell lymphoma treated with immunochemotherapy. British Journal of Haematology, 2014, 167, 133-136.	1.2	6
63	Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. Leukemia and Lymphoma, 2014, 55, 38-43.	0.6	72
64	MATILDE chemotherapy regimen for primary CNS lymphoma. Neurology, 2014, 82, 1370-1373.	1.5	38
65	Validation of the Advanced Polarimetric Doppler Weather Radar Simulator with Polar55C real observations. , 2014, , .		6
66	Genome-wide <i>scnDNA</i> profiling identifies clonal heterogeneity in marginal zone lymphomas. British Journal of Haematology, 2014, 164, 896-899.	1.2	0
67	CD49d Is the Strongest Flow Cytometry-Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2014, 32, 897-904.	0.8	162
68	MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma. Journal of Clinical Pathology, 2014, 67, 697-701.	1.0	34
69	Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. Haematologica, 2014, 99, 125-130.	1.7	77
70	Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. Haematologica, 2014, 99, 1611-1617.	1.7	29
71	Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica, 2014, 99, 489-496.	1.7	55
72	Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas. Leukemia Research, 2013, 37, 619-623.	0.4	24

#	ARTICLE	IF	CITATIONS
73	Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013, 31, 3351-3359.	0.8	54
74	Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. <i>Blood</i> , 2013, 122, 3759-3766.	0.6	82
75	NF10 Project: An International, Prospective, Observational Study Of Patients With Indolent Non-Follicular Lymphoma. Analysis Of First 215 Patients. <i>Blood</i> , 2013, 122, 1782-1782.	0.6	0
76	Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. <i>Leukemia and Lymphoma</i> , 2012, 53, 581-588.	0.6	74
77	Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas. <i>Cancer</i> , 2012, 118, 3954-3961.	2.0	21
78	Prognostic Relevance of CD49d Expression On B Leukemic Cells in Chronic Lymphocytic Leukemia. Meta-Analysis of Published and unpublished Individual Data From 3146 Patients. <i>Blood</i> , 2012, 120, 3871-3871.	0.6	1
79	Monocytosis Has Adverse Prognostic Significance and Impacts Survival in Patients with T-Cell Lymphomas.. <i>Blood</i> , 2012, 120, 2647-2647.	0.6	0
80	Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 986-993.	0.8	302
81	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604.	0.6	173
82	Integrated profiling of diffuse large B-cell lymphoma with 7q gain. <i>British Journal of Haematology</i> , 2011, 153, 499-503.	1.2	12
83	Gains of <i>MYC</i> locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>British Journal of Haematology</i> , 2011, 155, 274-277.	1.2	47
84	Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISTL). <i>Annals of Hematology</i> , 2011, 90, 323-330.	0.8	10
85	Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. <i>Hematological Oncology</i> , 2011, 29, 38-41.	0.8	29
86	Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. <i>Blood</i> , 2011, 118, 5759-5766.	0.6	34
87	Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study From the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2011, 29, 4227-4233.	0.8	47
88	Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. <i>Leukemia and Lymphoma</i> , 2011, 52, 771-775.	0.6	86
89	Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1867-1872.	0.6	43
90	Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-Cell Receptors. <i>Blood</i> , 2011, 118, 2847-2847.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. <i>Haematologica</i> , 2010, 95, 1792-1796.	1.7	91
92	Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. <i>European Journal of Haematology</i> , 2010, 84, 223-228.	1.1	77
93	The clinical and biological features of a series of immunophenotypic variant of B-CLL. <i>European Journal of Haematology</i> , 2010, 85, 120-129.	1.1	13
94	Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. <i>British Journal of Haematology</i> , 2010, 151, 221-231.	1.2	47
95	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , 2010, 151, 435-439.	1.2	20
96	Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. <i>Leukemia and Lymphoma</i> , 2010, 51, 422-429.	0.6	2
97	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 5101-5109.	0.8	400
98	ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 805-811.	0.8	256
99	Proposal and Validation of Prognostic Scoring Systems for IgG and IgA Monoclonal Gammopathies of Undetermined Significance. <i>Clinical Cancer Research</i> , 2009, 15, 4439-4445.	3.2	15
100	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. <i>European Journal of Haematology</i> , 2009, 82, 93-105.	1.1	21
101	Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2009, 83, 208-214.	1.1	8
102	Bisphosphonates associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time. <i>American Journal of Hematology</i> , 2009, 84, 850-852.	2.0	12
103	CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL. <i>Hematological Oncology</i> , 2009, 27, 140-147.	0.8	46
104	Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. <i>Cancer</i> , 2009, 115, 1906-1913.	2.0	6
105	Response-Guided ABVD Chemotherapy plus Involved-Field Radiation Therapy for Intermediate-Stage Hodgkin Lymphoma in the Pre-Positron Emission Tomography Era: A Gruppo Italiano Studio Linfomi (GISL) Prospective Trial. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 138-144.	1.4	9
106	First-Line Treatment of Multiple Myeloma in Elderly Patients: the GIMEMA (Gruppo Italiano Malattie) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 10, 906-922.	1.0	9
107	Front-Line Chemo-Immunotherapy Rituximab-FC + Rituximab Maintenance in Patients with Untreated Advanced Stage Non Follicular Lymphoma (INFL): Update of a Prospective Study of the Intergruppo Italiano Linfomi and Roche (ML18324).. <i>Blood</i> , 2009, 114, 2686-2686.	0.6	1
108	A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. <i>American Journal of Hematology</i> , 2008, 83, 349-354.	2.0	25

#	ARTICLE	IF	CITATIONS
109	Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. <i>Leukemia Research</i> , 2008, 32, 1628-1632.	0.4	1
110	Repetitive DNA Hypomethylation in Multiple Myeloma. <i>Blood</i> , 2008, 112, 2703-2703.	0.6	16
111	Biphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2007, 48, 56-64.	0.6	86
112	Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. <i>Haematologica</i> , 2007, 92, 56-65.	1.7	34
113	Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. <i>Cancer</i> , 2007, 109, 2077-2082.	2.0	50
114	Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. <i>British Journal of Haematology</i> , 2007, 136, 565-573.	1.2	66
115	R-CHOP vs R-MiniCEOP in Elderly Patients with Diffuse Large B-Cell Lymphoma (B-DLCL) Prospectively Selected by a Multidimensional Evaluation Scale: Preliminary Results of a Randomized Study Performed by Intergruppo Italiano Linfomi (IIL).. <i>Blood</i> , 2007, 110, 3429-3429.	0.6	1
116	Genome-Wide Analysis of DNA Copy Number in Multiple Myeloma Using High-Density SNP Arrays Reveals Clustering Patterns with Distinct Transcriptional Profiles.. <i>Blood</i> , 2007, 110, 2482-2482.	0.6	0
117	Splenic marginal zone lymphoma: a prognostic model for clinical use. <i>Blood</i> , 2006, 107, 4643-4649.	0.6	217
118	The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study. <i>European Journal of Haematology</i> , 2006, 76, 217-229.	1.1	8
119	Severe legionella pneumophila infection in a patient with hairy cell leukemia in partial remission after interferon treatment. <i>Hematological Oncology</i> , 2006, 9, 125-128.	0.8	9
120	Early Response to a Short Course of Induction Chemotherapy Overcomes the Prognostic Role of IPI in Patients with Aggressive NHL. Preliminary Results of the GISL LA05 Trial.. <i>Blood</i> , 2006, 108, 2434-2434.	0.6	3
121	Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. <i>Oncogene</i> , 2005, 24, 2461-2473.	2.6	118
122	Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 117-127.	1.5	49
123	ABVD Versus Modified Stanford V Versus MOPPEBVCAD With Optional and Limited Radiotherapy in Intermediate- and Advanced-Stage Hodgkin's Lymphoma: Final Results of a Multicenter Randomized Trial by the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2005, 23, 9198-9207.	0.8	167
124	Immunoglobulin M Monoclonal Gammopathies of Undetermined Significance and Indolent Waldenström's Macroglobulinemia Recognize the Same Determinants of Evolution Into Symptomatic Lymphoid Disorders: Proposal for a Common Prognostic Scoring System. <i>Journal of Clinical Oncology</i> , 2005, 23, 4662-4668.	0.8	73
125	Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing CCND1 and Negative for 14q32 Translocations. <i>Journal of Clinical Oncology</i> , 2005, 23, 7296-7306.	0.8	123
126	Prognostic Validation of the International Classification of Immunoglobulin M Gammopathies: A Survival Advantage for Patients with Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance?. <i>Clinical Cancer Research</i> , 2005, 11, 1786-1790.	3.2	61



#	ARTICLE	IF	CITATIONS
127	Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. <i>British Journal of Haematology</i> , 2004, 124, 289-298.	1.2	26
128	Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 211-215.	0.8	99
129	Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma. <i>Genes Chromosomes and Cancer</i> , 2003, 37, 261-269.	1.5	31
130	Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias. <i>British Journal of Haematology</i> , 2003, 121, 772-774.	1.2	7
131	Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide - Response to milishkin et al.. <i>British Journal of Haematology</i> , 2003, 123, 748-748.	1.2	0
132	Cell cycle regulators in multiple myeloma: Prognostic implications of p53 nuclear accumulation. <i>Human Pathology</i> , 2003, 34, 41-47.	1.1	19
133	Treatment of Indolent B-Cell Nonfollicular Lymphomas: Final Results of the LL01 Randomized Trial of the Gruppo Italiano per lo Studio dei Linfomi. <i>Journal of Clinical Oncology</i> , 2003, 21, 1459-1465.	0.8	23
134	Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). <i>British Journal of Haematology</i> , 2001, 114, 362-364.	1.2	59
135	Immunoreactivity for p27KIP1 and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma. <i>International Journal of Cancer</i> , 2001, 94, 599-604.	2.3	21
136	Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells. <i>Journal of Experimental Medicine</i> , 2001, 194, 1625-1638.	4.2	823
137	OPP-EBV-CAD Regimen as Salvage Treatment in Advanced Refractory or Resistant Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 2000, 40, 87-94.	0.6	2
138	Immunohistochemical Analysis of Cyclin D1 Shows Deregulated Expression in Multiple Myeloma with the t(11;14). <i>American Journal of Pathology</i> , 2000, 156, 1505-1513.	1.9	72
139	Detection of t(4;14)(p16.3;q32) Chromosomal Translocation in Multiple Myeloma by Double-Color Fluorescent In Situ Hybridization. <i>Blood</i> , 1999, 94, 724-732.	0.6	58
140	Molecular Analysis of 11q13 Breakpoints in Multiple Myeloma. <i>Blood</i> , 1999, 93, 1330-1337.	0.6	80
141	Molecular Analysis of 11q13 Breakpoints in Multiple Myeloma. <i>Blood</i> , 1999, 93, 1330-1337.	0.6	6
142	FGFR3 Gene Mutations Associated With Human Skeletal Disorders Occur Rarely in Multiple Myeloma. <i>Blood</i> , 1998, 92, 2987-2989.	0.6	36
143	A Novel Chromosomal Translocation t(4; 14)(p16.3; q32) in Multiple Myeloma Involves the Fibroblast Growth-Factor Receptor 3 Gene. <i>Blood</i> , 1997, 90, 4062-4070.	0.6	201
144	A pilot study on the use of the proMACE-cytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. , 1997, 79, 1234-1240.		9

#	ARTICLE	IF	CITATIONS
145	A CoDerative Study on ProMACE-dytaBOM in Aggressive Non-Hodgkin's Lymphomas. Leukemia and Lymphoma, 1994, 13, 111-118.	0.6	3
146	Peripheral neuropathy in IgM monoclonal gammopathy and wÅldenstrom's macroglobulinemia: A frequent complication in elderly males with low MAG-reactive serum monoclonal component. American Journal of Hematology, 1994, 45, 25-31.	2.0	73
147	No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone. Cancer, 1991, 68, 62-67.	2.0	17
148	Terminal Deoxynucleotidyl Transferase, Tdt, as a Marker for Leukemia and Lymphoma Cells. International Journal of Biological Markers, 1987, 2, 31-42.	0.7	5